Genetic risk of breast cancer

Minerva Endocrinologica

Volumn 34, Issue 4, 2009, Pages 295-309

  Nasir, A ^a   Shackelford, R E ^a   Anwar, F ^a   Yeatman, T J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Breast neoplasms; Gene expression profiling; Mutation; Risk factors

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; BRIP1 PROTEIN; CHECKPOINT KINASE 2; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PALB2 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE LKB1; PROTEIN P53; RAD50 PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; ANTINEOPLASTIC AGENT;

ALLELE; APOPTOSIS; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; COWDEN SYNDROME; DISEASE ASSOCIATION; FAMILY HISTORY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENOME ANALYSIS; HEREDITY; HETEROZYGOSITY LOSS; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LINKAGE ANALYSIS; MUTATIONAL ANALYSIS; PENETRANCE; PEUTZ JEGHERS SYNDROME; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; BREAST TUMOR; CARCINOMA; DRUG DELIVERY SYSTEM; FEMALE; GENETIC LINKAGE; GENETICS; NEOPLASM; PATHOLOGY; RISK; TUMOR GENE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; DRUG DELIVERY SYSTEMS; FEMALE; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LINKAGE (GENETICS); LOSS OF HETEROZYGOSITY; NEOPLASMS, HORMONE-DEPENDENT; PENETRANCE; RISK; RISK ASSESSMENT;

EID: 77952303881     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990;131:961-72.
2. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71. (Pubitemid 24345325)
3. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709.
4. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138-45.
5. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000;6:782-9.
6. Foulkes WD, Stefansson IM, Chappuis PO, Beǵin LR, Goffin JR, Wong N et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-5. (Pubitemid 37279334)
7. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-80.
8. Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 2007;31:121-8.
9. Honrado E, Benitez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 2005;18:1305-20. (Pubitemid 41348649)
10. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389-99.
11. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004;9:221-36. (Pubitemid 39545740)
12. Lakhani SR. The pathology of familial breast cancer: morphological aspects. Breast Cancer Res 1999;1:31-5.
13. Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998;83:2335-45.
14. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999;59:2011-7. (Pubitemid 29186179)
15. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003;9(10 Pt 1):3606-14.
16. Honrado E, Osorio A, Milne RL, Paz MF, Melchor L, Cascón A et al. Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod Pathol 2007;20:1298-306.
17. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8. (Pubitemid 34441658)
18. Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R et al. Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat 2009;22:22.
19. Chen DT, Nasir A, Venkataramu C, Fulp W, Gruidl M, Yeatman T. Evaluation of malignancy-risk gene signature in breast cancer patients. Breast Cancer Res Treat 2009 [Epub ahead of print].
20. Hall JM, Lee MK, Newman B, Morrow JE, Anderson IA, Huey B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9. (Pubitemid 120031871)
21. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
22. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
23. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
24. Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genet Epidemiol 2000;18:173-90.
25. A Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002;86:76-83. (Pubitemid 34146344)
26. Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res 1999;1:14-7.
27. Easton DF, Matthews FE, Ford D, Swerdlow AJ, Peto J. Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer 1996;65:284-94.
28. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997;349:1505-10.
29. J Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 2005;207:260-8.
30. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001;20:4621-8. (Pubitemid 32762434)
31. Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000;82:1932-7.
32. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184-92. (Pubitemid 43292562)
33. Nelen MR, Padberg GW, Peeters EA, Lin AY, van den Helm B, Frants RR et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996;13:114-6.
34. Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997;6:1383-7. (Pubitemid 27351082)
35. Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem. 2006;75:137-63.
36. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184-7.
37. Hemminki A, Tomlinson I, Markie D, Järvinen H, Sistonen P, Björkqvist AM et al. Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 1997;15:87-90. (Pubitemid 27014956)
38. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18:38-43. (Pubitemid 28027876)
39. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402-5. (Pubitemid 28168738)
40. Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 1999;155:337-42. (Pubitemid 29370383)
41. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001;121:1348-53. (Pubitemid 33140452)
42. Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ et al. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 2007;44:726-31.
43. Bignell GR, Barfoot R, Seal S, Collins N, Warren W, Stratton MR. Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res 1998;58:1384-6.
44. Chen J, Lindblom P, Lindblom A. A study of the PTEN/MMAC1 gene in 136 breast cancer families. Hum Genet 1998;102:124-5.
45. Guénard F, Labrie Y, Ouellette G, Beauparlant CJ, Bessette P, Chiquette J et al. Germline mutations in the breast cancer susceptibility gene PTEN are rare in highrisk non-BRCA1/2 French Canadian breast cancer families. Fam Cancer 2007;6:483-90.
46. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007;39:165-7.
47. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286: 2528-31.
48. M Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R et al Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
49. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-53.
50. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008;9:759-69.
51. Cimprich KA, Shin TB, Keith CT, Schreiber SL. cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein. Proc Natl Acad Sci U S A 1996;93:2850-5.
52. Shackelford RE, Innes CL, Sieber SO, Heinloth AN, Leadon SA, Paules RS. The Ataxia telangiectasia gene product is required for oxidative stress-induced G1 and G2 checkpoint function in human fibroblasts. J Biol Chem 2001;276:21951-9.
53. Shackelford RE, Fu Y, Manuszak RP, Brooks TC, Sequeira AP, Wang S et al. Iron chelators reduce chromosomal breaks in ataxia-telangiectasia cells. DNA Repair (Amst) 2006;5:1327-36.
54. Swift M, Sholman L, Perry M, Chase C. Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res 1976;36:209-15.
55. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987;316:1289-94.
56. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008;359:2143-53.
57. Byrnes GB, Southey MC, Hopper JL. Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res 2008;10:208.
58. Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 2009;85:427-46.
59. Ye C, Cai Q, Dai Q, Shu XO, Shin A, Gao YT et al. Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival. Cancer 2007;109:1729-35. (Pubitemid 46668533)
60. Tommiska J, Bartkova J, Heinonen M, Hautala L, Kilpivaara O, Eerola H et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 2008;27:2501-6.
61. Vo QN, Kim WJ, Cvitanovic L, Boudreau DA, Ginzinger DG, Brown KD. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene 2004;23:9432-7. (Pubitemid 40069676)
62. Junttila MR, Evan GI. p53 a Jack of all trades but master of none. Nat Rev Cancer 2009;9:821-9.
63. Shackelford RE, Kaufmann WK, Paules RS. Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ Health Perspect 1999;107(Suppl 1):5-24. (Pubitemid 29164196)
64. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71:747-52.
65. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 2009;4:461-87.
66. Gatei M, Zhou BB, Hobson K, Scott S, Young D, Khanna KK. Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J Biol Chem 2001;276:17276-80.
67. Kitagawa R, Kastan MB. The ATM-dependent DNA damage signaling pathway. Cold Spring Harb Symp Quant Biol 2005;70:99-109. (Pubitemid 44124861)
68. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999;286:1162-6. (Pubitemid 129515811)
69. Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999;18:4047-54.
70. Herzog KH, Chong MJ, Kapsetaki M, Morgan JI, McKinnon PJ. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 1998;280:1089-91. (Pubitemid 28234952)
71. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005;97:813-22. (Pubitemid 40909124)
72. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006;38:873-5.
73. Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 2001;105:149-60. (Pubitemid 32323924)
74. Peng M, Litman R, Jin Z, Fong G, Cantor SB. BACH1 is a DNA repair protein supporting BRCA1 damage response. Oncogene 2006;25:2245-53.
75. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006;38:1239-41.
76. Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group. J Nat Genet 2005;37:934-5.
77. Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, Rio P et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 2005;37:931-3.
78. Litman R, Peng M, Jin Z, Zhang F, Zhang J, Powell S et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005;8:255-65.
79. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007;39:162-4.
80. Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundan T et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 2006;27:1593-9. (Pubitemid 44288048)
81. Rahman N, Scott RH. Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum Mol Genet 2007;16(Spec No 1):R60-6.
82. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007;39:352-8.
83. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG et al. Genome-wide assoiation study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
84. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-4.
85. Antoniou AC, Sinilnikova OM, Simard J et al. RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007;81:1186-200.
86. Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008;82:937-48.
87. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-406.
88. Hopper JL, Carlin JB. Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. Am J Epidemiol 1992;136:1138-47.
89. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
90. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
91. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.